Dexrazoxane for preventing cardiotoxicity in children and young people (< 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer

This activity is now closed…

Unfortunately, this activity is now closed and no more online responses will be accepted.

Return to overview page